PLP139-151 - CFA-Induced Remitting Relapse in SJL Mice

Remitting Relapsing PLP-induced EAE Efficacy Model for MS Research

PLP is a major protein component of CNS myelin. Sections of PLP, such as 139-151 peptide, are encephalitogenic to certain mouse strains. PLP injected in Swiss Jim Lambert (SJL) mice together with pertussis toxin (PT) will lead to remitting- relapsing disease. Relapses are associated with epitope spreading in which T cell reactivity to secondary endogenous peptides that emerge as a consequence of the initial phase of myelin destruction. Remissions are associated with a temporary loss of inflammatory cells from the CNS.

Remitting relapsing PLP-induced EAE Efficacy Model for MS Research

In our Multiple Sclerosis (MS) efficacy model, disease is induced on day 0 using PLP emulsified with CFA. Additionally, to increase the susceptibility of the BBB, all animals are subject to supplemental immunostimulation with a PT injection on day 0 and day 2. The disease typically develops between days 10–12 with the peak occurring between days 14-16. If the relapse phase is required, the study can be extended such that a second disease peak will be apparent between days 25-30. This disease is characterized by paralysis attacks of all 4 paws and is typically used for testing the activity of a compound by injection of the compound between phases.
 

Assessments Include:

  • Clinical Score
  • Histology for cellular infiltration
  • Immunohistochemistry (IHC) for demyelination
  • Biomarkers
  • PK

See below data to learn more. 

Contact a scientist to discuss your requirements today. 

 

 

SPECIES AVAILABLE:

  • mouse PLP

 

Request Study Proposal
preclinical models of EAE for the study of MS (MOG-EAE, MBP-EAE, PLP-EAE)

 


CONTACT US:

1-888-876-3246
+41-44 986-2628
email us